Idelalisib Approval Status beta

  • FDA approved: No
  • Generic name: idelalisib
  • Company: Gilead Sciences, Inc.
  • Treatment for: Non-Hodgkin's Lymphoma

Idelalisib is a phosphoinositide 3-kinase (PI3K) delta inhibitor in development for the treatment of indolent non-Hodgkin’s lymphoma.

FDA Approval Status for idelalisib

DateArticle
Jan 13, 2014U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Sep 11, 2013Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent Non-Hodgkin's Lymphoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web3)